Drugs / Bendamustine
Bendamustine
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | TREANDA | — | 2008-03-20 | fda.gov ↗ |
Trials 260 · started per year
today
US approved 2008
1
2
4
3
1
4
10
28
29
27
19
16
12
16
12
10
6
7
6
13
5
6
9
11
2
2001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
Also used as a comparator or background therapy in 140 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT03295240 Background | Sep 2017 → Jan 2024 | mantle cell lymphoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 0 | NCT01022021 Comparator | Jan 2010 → Apr 2014 | lymphoma | University of Kansas Medical Center | Completed | No outcome recorded |
| Phase 140 trials | ||||||
| Phase 1 | NCT07166549 Background | Jun 2026 → Nov 2028 expected | B-cell neoplasm, lymphoid leukemia | University Hospital, Basel, Switzerland | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06094842 Background | Apr 2025 → Mar 2028 | prostate small cell carcinoma | Fred Hutchinson Cancer Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT06483048 Background | Sep 2024 → Sep 2028 expected | fallopian tube carcinosarcoma, ovarian carcinosarcoma, primary peritoneal carcinoma | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 1 | NCT06138132 Background | Apr 2024 → Jun 2027 expected | primary progressive multiple sclerosis, secondary progressive multiple sclerosis | Stanford University | Recruiting | No outcome recorded |
| Phase 1 | NCT06308978 Background | Mar 2024 → Sep 2027 expected | anti-neutrophil cytoplasmic antibody-associated vasculitis, idiopathic inflammatory myopathy, lupus nephritis, systemic lupus erythematosus +1 | Fate Therapeutics | Recruiting | No outcome recorded |
| Phase 1 | NCT06191887 Background | Mar 2024 → Dec 2040 expected | Richter transformation, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma +2 | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 1 | NCT06241456 Background | Jan 2024 → May 2029 expected | neoplasm | Fate Therapeutics | Recruiting | No outcome recorded |
| Phase 1 | NCT06043713 Background | Dec 2023 → Jan 2028 expected | metastatic malignant neoplasm | Fred Hutchinson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT05950334 Background | Nov 2023 → Jun 2025 | B-cell non-Hodgkin lymphoma | Fate Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT05934097 Background | Dec 2022 → May 2026 | diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma | Fate Therapeutics | Withdrawn | No outcome recorded |
| Phase 1 | NCT04892277 Background | Oct 2022 → Mar 2028 expected | Richter transformation, chronic lymphocytic leukemia/small lymphocytic lymphoma | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 1 | NCT05352828 Background | Jul 2022 → Dec 2025 overdue | classic Hodgkin lymphoma | Tessa Therapeutics | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04809766 Background | Dec 2021 → Oct 2024 | pancreatic ductal adenocarcinoma | Fred Hutchinson Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT05182073 Background | Nov 2021 → Sep 2024 | plasma cell myeloma | Fate Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04526834 Background | Sep 2021 → Nov 2022 overdue | anaplastic large cell lymphoma, peripheral T-cell lymphoma, not otherwise specified, primary mediastinal large B-cell lymphoma | Tessa Therapeutics | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04629729 Background | Jul 2021 → Jun 2025 overdue | B-cell chronic lymphocytic leukemia, precursor B-cell acute lymphoblastic leukemia | Fate Therapeutics | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04674813 Background | Feb 2021 → Dec 2025 | plasma cell myeloma | Juno Therapeutics, a Subsidiary of Celgene | Completed | No outcome recorded |
| Phase 1 | NCT04223765 Background | Nov 2020 → Mar 2028 expected | MALT lymphoma, follicular lymphoma, mantle cell lymphoma, nodal marginal zone B-cell lymphoma +1 | UNC Lineberger Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT04245722 Background | Mar 2020 → Sep 2023 | B-cell chronic lymphocytic leukemia | Fate Therapeutics | Terminated | No outcome recorded |
| Phase 1 | NCT04049825 Background | Nov 2019 → Mar 2025 | relapsed/refractory diffuse large B-cell lymphoma | Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04023071 Background | Oct 2019 → Oct 2023 | B-cell neoplasm, acute myeloid leukemia | Fate Therapeutics | Terminated | No outcome recorded |
| Phase 1 | NCT03696784 Background | Mar 2019 → Aug 2025 overdue | B-cell non-Hodgkin lymphoma, immunoproliferative disorder, lymphatic system disorder | UNC Lineberger Comprehensive Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03602157 Background | Oct 2018 → Dec 2025 overdue | B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma, Sezary syndrome, immunoproliferative disorder, lymphomatoid papulosis +3 | UNC Lineberger Comprehensive Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03424122 Background | Jul 2018 → Jun 2022 | B-cell non-Hodgkin lymphoma | Incyte Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02257242 Background | May 2017 → Aug 2020 | Waldenstrom macroglobulinemia, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma | Brown University | Completed | No outcome recorded |
| Phase 1 | NCT03039114 Background | Feb 2017 → Mar 2021 | lymphoma | Incyte Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02194374 Background | Jan 2015 → Jun 2017 | leukemia | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT02130869 Background | Oct 2014 → Dec 2017 | lymphoma, neuroblastoma | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02240719 Background | Oct 2014 → Apr 2018 | B-cell chronic lymphocytic leukemia, Hodgkins lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma +1 | University of California, Davis | Completed | No outcome recorded |
| Phase 1 | NCT02153580 Background | Sep 2014 → Sep 2026 expected | B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma, B-cell prolymphocytic leukemia, Burkitt lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma +7 | City of Hope Medical Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02148913 Comparator | Jun 2014 → Dec 2018 | plasma cell myeloma | Corewell Health West | Completed | No outcome recorded |
| Phase 1 | NCT01479842 Background | Mar 2014 → Jul 2026 overdue | MALT lymphoma, Waldenstrom macroglobulinemia, diffuse large B-cell lymphoma, mantle cell lymphoma +2 | Kami Maddocks, MD | Active not recruiting | No outcome recorded |
| Phase 1 | NCT01671904 Background | Jan 2014 → Aug 2018 | B-cell chronic lymphocytic leukemia | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01400685 Background | Dec 2012 → Dec 2017 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 1 | NCT01644253 Background | Sep 2012 → Feb 2020 | B-cell chronic lymphocytic leukemia, peripheral T-cell lymphoma, not otherwise specified | Aptevo Therapeutics | Terminated | No outcome recorded |
| Phase 1 | NCT01594229 Background | May 2012 → Jul 2020 | non-Hodgkin lymphoma | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT01429025 Background | May 2012 → Nov 2014 | indolent B-cell non-Hodgkin lymphoma | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 1 | NCT01491841 Background | Nov 2011 → Nov 2016 | non-Hodgkin lymphoma | Anne Beaven, MD | Completed | No outcome recorded |
| Phase 1 | NCT01317901 Background | May 2011 → Apr 2013 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Aptevo Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT00868413 Comparator | Nov 2009 → May 2013 | B-cell chronic lymphocytic leukemia | AbbVie | Completed | No outcome recorded |
| Phase 1/217 trials | ||||||
| Phase 1/2 | NCT07225985 Background | Apr 2026 → Sep 2030 expected | T-cell non-Hodgkin lymphoma | Fred Hutchinson Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07059650 Background | Aug 2025 → Oct 2030 expected | diffuse large B-cell lymphoma | Dizal Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06090864 Background | Apr 2024 → Jul 2026 overdue | Hodgkins lymphoma | UNC Lineberger Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05300282 Background | Feb 2023 → Apr 2027 expected | Hodgkins lymphoma | Fondazione Italiana Linfomi - ETS | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05451771 Comparator | Oct 2022 → Sep 2027 expected | AL amyloidosis | Columbia University | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04727151 Background | Apr 2021 → Dec 2023 | gastroesophageal cancer | Triumvira Immunologics, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT04663347 Background | Nov 2020 → Sep 2027 expected | diffuse large B-cell lymphoma, follicular lymphoma | Genmab | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03997968 Background | Oct 2019 → Nov 2024 | B-cell chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, head and neck squamous cell carcinoma +7 | Cyteir Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT03187210 Background | Sep 2018 → Nov 2023 | lymphoma | Insel Gruppe AG, University Hospital Bern | Suspended | No outcome recorded |
| Phase 1/2 | NCT02678299 Background | Feb 2016 → Feb 2022 | lymphoma | University of Aarhus | Unknown | No outcome recorded |
| Phase 1/2 | NCT02348216 Background | Apr 2015 → Jul 2023 | follicular lymphoma, high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma | Kite, A Gilead Company | Completed | No outcome recorded |
| Phase 1/2 | NCT02257567 Background | Oct 2014 → Oct 2021 | lymphoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/2 | NCT02134262 Background | May 2014 → Mar 2017 | B-cell non-Hodgkin lymphoma | Jichi Medical University | Unknown | No outcome recorded |
| Phase 1/2 | NCT01664910 Background | Oct 2012 → Jun 2023 | hematopoietic and lymphoid cell neoplasm | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT01369849 Background | Sep 2011 → Feb 2014 | chronic lymphocytic leukemia/small lymphocytic lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT01238146 Background | Oct 2010 → Apr 2012 | MALT lymphoma, mantle cell lymphoma, nodal marginal zone B-cell lymphoma, splenic marginal zone lymphoma | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT01188681 Comparator | Sep 2010 → Dec 2014 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Aptevo Therapeutics | Completed | No outcome recorded |
| Phase 227 trials | ||||||
| Phase 2 | NCT07189065 Comparator | Nov 2025 → Dec 2027 expected | diffuse large B-cell lymphoma | Guangzhou Lupeng Pharmaceutical Company LTD. | Recruiting | No outcome recorded |
| Phase 2 | NCT07208981 Comparator | Aug 2025 → Jun 2028 expected | marginal zone lymphoma | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT06563778 Comparator | Sep 2024 → Sep 2026 expected | classic Hodgkin lymphoma | Chinese PLA General Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05848765 Comparator | Sep 2023 → May 2029 expected | follicular lymphoma | University of Birmingham | Recruiting | No outcome recorded |
| Phase 2 | NCT05508867 Comparator | Oct 2022 → Sep 2025 | classic Hodgkin lymphoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT05025423 Background | Jun 2022 → May 2025 | mantle cell lymphoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded |
| Phase 2 | NCT05249959 Background | Mar 2022 → Mar 2026 overdue | mantle cell lymphoma | Fondazione Italiana Linfomi - ETS | Recruiting | No outcome recorded |
| Phase 2 | NCT04138875 Comparator | Jan 2022 → Sep 2023 | classic Hodgkin lymphoma, infectious mononucleosis, post-transplant lymphoproliferative disease | Yale University | Withdrawn | No outcome recorded |
| Phase 2 | NCT04844866 Comparator | Aug 2021 → Jan 2025 overdue | diffuse large B-cell lymphoma | Miltenyi Biomedicine GmbH | Recruiting | No outcome recorded |
| Phase 2 | NCT04792489 Background | May 2021 → Dec 2026 expected | Richter transformation, central nervous system non-hodgkin lymphoma, high grade B-cell lymphoma, mantle cell lymphoma +1 | Miltenyi Biomedicine GmbH | Recruiting | No outcome recorded |
| Phase 2 | NCT04268706 Background | Feb 2021 → May 2025 overdue | classic Hodgkin lymphoma | Tessa Therapeutics | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04515238 Background | Oct 2020 → Dec 2026 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | German CLL Study Group | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03834688 Background | Jan 2020 → Oct 2022 | mantle cell lymphoma | PrECOG, LLC. | Completed | No outcome recorded |
| Phase 2 | NCT03856216 Background | Oct 2019 → Oct 2025 | B-cell acute lymphoblastic leukemia | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT04083495 Background | Sep 2019 → Feb 2028 expected | peripheral T-cell lymphoma, not otherwise specified | UNC Lineberger Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT03623373 Background | Nov 2018 → Feb 2020 | mantle cell lymphoma | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT03269669 Comparator | Jan 2018 → Dec 2025 overdue | follicular lymphoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03492775 Comparator | Dec 2017 → Nov 2021 | indolent B-cell non-Hodgkin lymphoma | Prof. Dr. Wolfgang Hiddemann | Completed | No outcome recorded |
| Phase 2 | NCT02747732 Background | Dec 2016 → Jun 2020 | indolent B-cell non-Hodgkin lymphoma, primary mediastinal large B-cell lymphoma | Meirav Kedmi MD | Unknown | No outcome recorded |
| Phase 2 | NCT02836639 Background | Feb 2016 → Dec 2019 | non-Hodgkin lymphoma | Pusan National University Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02594163 Background | Oct 2015 → Sep 2017 | follicular lymphoma, relapsed/refractory diffuse large B-cell lymphoma | Seagen Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT02424851 Comparator | Nov 2014 → Apr 2020 | chronic kidney disease, plasma cell myeloma | Oxford University Hospitals NHS Trust | Completed | No outcome recorded |
| Phase 2 | NCT01490723 Background | Jan 2013 → Apr 2019 | leukemia, lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01415752 Background | Aug 2012 → Feb 2023 overdue | mantle cell lymphoma | Eastern Cooperative Oncology Group | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01466153 Background | Feb 2012 → Jan 2016 | chronic lymphocytic leukemia/small lymphocytic lymphoma | MedImmune LLC | Completed | No outcome recorded |
| Phase 2 | NCT01423539 Background | Oct 2011 → Feb 2014 | diffuse large B-cell lymphoma | Genentech, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT00899431 Comparator | May 2009 → Oct 2018 | B-cell chronic lymphocytic leukemia | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT07634471 Background | Jun 2026 → Jul 2032 expected | follicular lymphoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 2/3 | NCT02763319 Background | Nov 2016 → Jun 2024 | diffuse large B-cell lymphoma | Incyte Corporation | Completed | No outcome recorded |
| Phase 348 trials | ||||||
| Phase 3 | NCT07139873 Comparator | Sep 2025 → Jan 2029 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | Dizal Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT06911502 Comparator | Jul 2025 → Apr 2028 expected | follicular lymphoma | Celgene Corporation | Recruiting | No outcome recorded |
| Phase 3 | NCT06970743 Comparator | May 2025 → Nov 2029 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | BeOne Medicines | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06522737 Comparator | May 2025 → Feb 2028 expected | lymphoma | SecuraBio | Recruiting | No outcome recorded |
| Phase 3 | NCT06846671 Comparator | Apr 2025 → May 2028 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | BeOne Medicines | Recruiting | No outcome recorded |
| Phase 3 | NCT06549595 Comparator | Aug 2024 → Nov 2031 expected | follicular lymphoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT06496308 Background | Jul 2024 → Jul 2027 expected | mantle cell lymphoma | Ruijin Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT06465446 Comparator | Jun 2024 → Jun 2026 overdue | classic Hodgkin lymphoma | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06363994 Comparator | May 2024 → Jun 2031 expected | mantle cell lymphoma | InnoCare Pharma Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT06313996 Comparator | Mar 2024 → Oct 2031 | B-cell neoplasm | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Withdrawn | No outcome recorded |
| Phase 3 | NCT06205290 Comparator | Jan 2024 → Oct 2031 | B-cell chronic lymphocytic leukemia | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Withdrawn | No outcome recorded |
| Phase 3 | NCT06170489 Comparator | Dec 2023 → May 2025 overdue | Hodgkins lymphoma | Shanghai Junshi Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06091254 Comparator | Dec 2023 → Feb 2028 expected | follicular lymphoma | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT06084936 Comparator | Oct 2023 → Aug 2027 expected | lymphoma | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 3 | NCT05888493 Background | Oct 2023 → Jul 2028 expected | follicular lymphoma | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06006117 Comparator | Sep 2023 → Sep 2027 expected | marginal zone lymphoma | The Lymphoma Academic Research Organisation | Recruiting | No outcome recorded |
| Phase 3 | NCT05624554 Comparator | Mar 2023 → May 2027 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05371093 Comparator | Sep 2022 → Oct 2030 expected | lymphoma | Kite, A Gilead Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04849715 Comparator | Mar 2022 → Aug 2030 | mantle cell lymphoma | Incyte Corporation | Withdrawn | No outcome recorded |
| Phase 3 | NCT05023980 Comparator | Sep 2021 → Jul 2025 overdue | chronic lymphocytic leukemia/small lymphocytic lymphoma | Loxo Oncology, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04666038 Comparator | Mar 2021 → Aug 2023 overdue | chronic lymphocytic leukemia/small lymphocytic lymphoma | Loxo Oncology, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04628494 Comparator | Jan 2021 → Oct 2025 overdue | diffuse large B-cell lymphoma | Genmab | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04236141 Background | Jul 2020 → Jul 2021 | diffuse large B-cell lymphoma | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 3 | NCT04285567 Comparator | May 2020 → Mar 2024 | B-cell chronic lymphocytic leukemia | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT04002297 Comparator | Aug 2019 → Mar 2027 expected | mantle cell lymphoma | BeOne Medicines | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03570892 Background | May 2019 → May 2021 | non-Hodgkin lymphoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT03836261 Comparator | Feb 2019 → Jan 2027 expected | B-cell chronic lymphocytic leukemia | Acerta Pharma BV | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03593018 Comparator | Nov 2018 → Feb 2021 | angioimmunoblastic T-cell lymphoma | The Lymphoma Academic Research Organisation | Completed | No outcome recorded |
| Phase 3 | NCT02972840 Background | Apr 2017 → Feb 2027 expected | mantle cell lymphoma | Acerta Pharma BV | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02970318 Comparator | Feb 2017 → Sep 2021 overdue | B-cell chronic lymphocytic leukemia | Acerta Pharma BV | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02950051 Comparator | Dec 2016 → Feb 2024 | B-cell chronic lymphocytic leukemia | German CLL Study Group | Completed | No outcome recorded |
| Phase 3 | NCT02626455 Background | Jan 2016 → Sep 2023 | non-Hodgkin lymphoma | Bayer | Terminated | No outcome recorded |
| Phase 3 | NCT02576275 Background | Dec 2015 → Nov 2016 | chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, marginal zone lymphoma | SecuraBio | Withdrawn | No outcome recorded |
| Phase 3 | NCT02005471 Comparator | Mar 2014 → May 2017 | B-cell chronic lymphocytic leukemia | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01980888 Background | Feb 2014 → May 2016 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Gilead Sciences | Terminated | No outcome recorded |
| Phase 3 | NCT01974440 Background | Jan 2014 → May 2022 | lymphoma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT01886872 Comparator | Jan 2014 → Aug 2018 overdue | B-cell chronic lymphocytic leukemia | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01889069 Background | Jul 2013 → May 2019 | lymphoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01776840 Background | May 2013 → Jun 2021 | mantle cell lymphoma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT01732926 Background | Jan 2013 → May 2016 | non-Hodgkin lymphoma | Gilead Sciences | Terminated | No outcome recorded |
| Phase 3 | NCT01724021 Background | Dec 2012 → Jan 2015 | diffuse large B-cell lymphoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT02063685 Background | Jul 2012 → Dec 2021 | follicular lymphoma | Fondazione Italiana Linfomi - ETS | Completed | No outcome recorded |
| Phase 3 | NCT01569295 Background | Jun 2012 → Jun 2019 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01650701 Comparator | Feb 2012 → May 2017 | follicular lymphoma | The Lymphoma Academic Research Organisation | Completed | No outcome recorded |
| Phase 3 | NCT01476787 Comparator | Dec 2011 → Apr 2024 | follicular lymphoma | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT01332968 Background | Jul 2011 → Feb 2016 | non-Hodgkin lymphoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01232556 Comparator | Apr 2011 → Mar 2014 | non-Hodgkin lymphoma | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT01077518 Comparator | Aug 2010 → Jan 2018 | follicular lymphoma | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT06761911 Comparator | Dec 2024 → Dec 2025 overdue | Hodgkins lymphoma | Xiuhua Sun | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT03817853 Background | Feb 2019 → Aug 2020 | follicular lymphoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05813132 Comparator | Nov 2022 → Dec 2023 | lymphoma | Rehab Werida | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT03914885 Background | — | Hodgkins lymphoma | UNC Lineberger Comprehensive Cancer Center | No longer available | No outcome recorded |
Press releases naming this drug 14 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-12-07 | Roche Global Development | New data presented at ASH 2020 reinforces the benefit/risk profile of fixed-duration Polivy plus bendamustine and MabThera/Rituxan in patients with relapsed or refractory diffuse large B-cell lymphoma roche.com ↗ |
| 2017-09-18 | Roche Global Development | Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan helped people with previously treated chronic lymphocytic leukaemia live longer without their disease worsening compared to bendamustine plus MabThera/Rituxan roche.com ↗ |
| 2016-11-02 | Teva Branded Pharmaceutical Products R&D, Inc. | CMS Establishes Unique J-Code for BENDEKA® (Bendamustine Hydrochloride) Injection tevapharm.com ↗ |
| 2016-06-16 | Roche Global Development | Roche's Gazyvaro approved in Europe in combination with bendamustine for people with previously treated follicular lymphoma roche.com ↗ |
| 2016-06-10 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Favorable Court Ruling in TREANDA® (bendamustine hydrochloride) Patent Infringement Litigation tevapharm.com ↗ |
| 2016-01-28 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva and Eagle Pharmaceuticals Announce Commercial Availability of BENDEKA™ (bendamustine hydrochloride) Injection tevapharm.com ↗ |
| 2015-12-08 | Gilead Sciences | Phase 3 Results for Zydelig® With Bendamustine and Rituximab for Relapsed Chronic Lymphocytic Leukemia (CLL) Presented at American Society of Hematology Annual Meeting gilead.com ↗ |
| 2015-12-08 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Pharmaceuticals and Eagle Pharmaceuticals Announce FDA Approval of BENDEKA™ (bendamustine hydrochloride) Injection tevapharm.com ↗ |
| 2015-11-16 | Gilead Sciences | Gilead’s Zydelig® Combined with Bendamustine and Rituximab Shows Superior Efficacy to Bendamustine/Rituximab in Phase 3 Study of Patients with Relapsed Chronic Lymphocytic Leukemia gilead.com ↗ |
| 2015-04-14 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva and Eagle Pharmaceuticals Announce NDA for Bendamustine Rapid Infusion Product Accepted for Filing tevapharm.com ↗ |
| 2015-02-17 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva and Eagle Pharmaceuticals Announce Teva’s License to Commercialize Eagle’s Bendamustine Rapid Infusion Product tevapharm.com ↗ |
| 2014-11-18 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Launches Liquid Formulation of TREANDA® (bendamustine HCI) Injection in U.S. tevapharm.com ↗ |
| 2013-11-27 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Additional Regulatory Exclusivity for TREANDA® (Bendamustine HCI) for Injection tevapharm.com ↗ |
| 2013-09-17 | Teva Branded Pharmaceutical Products R&D, Inc. | FDA Approves Teva’s TREANDA® (bendamustine HCI) Injection, a New Liquid Formulation tevapharm.com ↗ |
Evidence & citations 22 cited values
Every value below carries the sentence it was read from. 402 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bendamustine | “This is a phase 1/2 open label study to assess the safety and efficacy of pixantrone in combination with bendamustine, etoposide and , for CD20 positive B-cell lymphomas,...” NCT02678299 ↗373“Patients receive a preparative lymphodepleting chemotherapy of intravenous cyclophosphamide and fludarabine from day -5 until day -3 (or Bendamustine on day -3 and day -2),...” NCT07166549 ↗ “Clinical and safety outcomes of BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) versus CEM (Carboplatin, Etoposide, Melphalan) in lymphoma patients as a conditioning...” PMID 39134959 ↗ Aug 2024 “A Phase 1, Multi-center, Open-label, Uncontrolled, Dose-escalation Trial to Evaluate the Safety of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With...” NCT04049825 ↗ “The patients will be given Bendamustine (90mg/m2 d1,2, every 28 days for total 6 courses) combined with Rituximab (375mg/m2 d0, every 28 days for total 6 courses) followed by...” NCT04842318 ↗ “During the induction therapy phase, patients will receive 90 mg/m2 of bendamustine and 375 mg/m2 zuberitamab from cycles 1 to 3, followed by 150 mg of orelabrutinib and 375...” NCT07008053 ↗ “Subjects will receive a lymphodepletion regimen of bendamustine 70 mg/m2 IV and fludarabine 30 mg/m2 each as a daily infusion for 3 consecutive days prior to the...” NCT06090864 ↗ “A Phase 1b, Multicenter, Open-label Study of Acalabrutinib in Combination With Bendamustine and Rituximab (BR) or Venetoclax and Rituximab (VR) in Subjects With Mantle Cell Lymphoma” NCT02717624 ↗ “The study objectives of this study are to determine the effects, safety, and pharmacokinetics of bendamustine for multiple myeloma to a regimen of bendamustine and prednisolone.” NCT01179490 ↗ “Drug: Bendamustine Schedule: Day 2: Bendamustine 90mg/mq Day 3: Bendamustine 90mg/mq for a maximum of 4 cycles Other Name: Ribomustin” NCT05660993 ↗ “A Phase II Trial of High-dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) in the Up-front Treatment of Multiple Myeloma” NCT02416206 ↗ “CD30.CAR-T cells will be infused once following the completion of lymphodepleting chemotherapy with Bendamustine and Fludarabine.” NCT04526834 ↗ “Bendamustine will be administered at a dose 90 mg/m2 i.v. day 2 \& 3 of cycle 1, then on day 1 \& 2 of each subsequent cycle.” NCT05868395 ↗ “Oral formulation of bendamustine hydrochloride for patients with advanced solid tumors; a phase 1 study.” PMID 36331674 ↗ Nov 2022 “Chemotherapy regimen consisting of bendamustine intravenously on days -7 and -6 at 200 mg/m2” NCT02278796 ↗ “either rituximab + gemcitabine + oxaliplatin [R-GemOx], or bendamustine + rituximab [BR]” NCT07226752 ↗ “either rituximab + gemcitabine + oxaliplatin [R-GemOx], or bendamustine + rituximab [BR]” NCT04628494 ↗ “Bendamustine will be given by intravenous infusion for 2 days out of each 28 day cycle” NCT00868413 ↗ “Bendamustine 90 mg/m\^2 administered intravenously at protocol-defined timepoints.” NCT03039114 ↗ “Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab” NCT04844866 ↗ “Lymphodepleting chemotherapy (fludarabine with cyclophosphamide or bendamustine)” NCT03570892 ↗ “fludarabine/cyclophosphamide/rituximab (FCR), bendamustine/rituximab (BR)” NCT03836261 ↗ “bendamustine 90 mg/m2/day was administered to the former on days 1 and 2” PMID 35796785 ↗ Jul 2022 “Bendamustine intravenously once daily on days -7 and -6 at 200 mg/m2/day” NCT03187210 ↗ “Bendamustine; Specification: 100mg per vial; 90mg/m2 d1-2, ivgtt.” NCT07072221 ↗ “bendamustine hydrochloride IV over 1 hour on days 1 and 2” NCT01216683 ↗ “Bendamustine direct intervenous 90 mg/m² day 1 and day 2” NCT01457144 ↗ “Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1” NCT02148913 ↗ “Bendamustine 160 mg/m2 for 2 days (D-8 and D-7)” NCT02008006 ↗ “bendamustine 75 mg/m2 over 1 h on days 2 and 3” NCT03392714 ↗ “Bendamustine 90 mg/m\^2 i.v. daily for 2 days” NCT05888493 ↗ “bendamustine (SyB L-0501: 90 mg/m\^2/day)” NCT01849848 ↗ “Bendamustine 70mg IV day 2 and ady 3” NCT01612988 ↗ “Azacitidine, Bendamustine, Bleomycin” NCT02788201 ↗ “Bendamustine: 90 mg/m2, IV, d1-d2” NCT07059650 ↗ “* Bendamustine 90mg/m2, IV, D1-2” NCT05245656 ↗ “B（Bendamustine）：90mg/m2·d，d1-2” NCT03980002 ↗ “Ofatumumab + Bendamustine” NCT01437709 ↗ “Bendamustine, Rituximab” NCT06549595 ↗ “SDX-105 (Bendamustine)” NCT00069758 ↗ “Bendamustine (Treanda)” NCT00856830 ↗ “Bendamustine infusion” NCT05025423 ↗ “bendamustine, or” NCT04727151 ↗ “Bendamustine” NCT06138132 ↗ |
| Known as | BEN | “Bendamustine (BEN)” NCT02763319 ↗ |
| Known as | Bendamustine (Treanda) | “Bendamustine (Treanda)” NCT00856830 ↗ |
| Known as | Bendamustine (Treanda; Ribomustin) | “Bendamustine (Treanda; Ribomustin)” NCT01221103 ↗ |
| Known as | Bendamustine / Brand: Treanda | “Bendamustine / Brand: Treanda” NCT01131247 ↗ |
| Known as | Bendamustine HCl | “The purpose of this study is to determine whether bendamustine HCl for injection is safe and effective in the treatment of Rituximab refractory or relapsed B-cell indolent lymphoma.” NCT01570049 ↗3“Bendamustine HCl is a chemotherapy agent that is effective in treating patients with various diseases, including non-Hodgkin's lymphoma, multiple myeloma, and breast cancer.” NCT00705250 ↗ “bendamustine HCL 90 mg/m2 intravenously on days 1(± 1 day) and 2 (± 1 day) every 28 days” NCT00867503 ↗ “Drug: Bendamustine HCl” NCT00139841 ↗ |
| Known as | bendamustine hydrochloride | “The purpose of this study is to assess the antitumor effects and safety of bendamustine hydrochloride (SyB L-0501) in patients with indolent B-cell non-Hodgkin's lymphoma or...” NCT00612183 ↗35“The purpose of this study is to assess the tolerability, pharmacokinetics and antitumor effect of bendamustine hydrochloride (SyB L-0501) in patients with indolent B-cell...” NCT00389051 ↗ “Drugs used in chemotherapy, such as bendamustine hydrochloride, also work in different ways to kill cancer cells or stop them from dividing.” NCT01429025 ↗ “A Multicenter, Open-Label, Phase 2 Study of SyB L-0501 (Bendamustine Hydrochloride) for Patients With Multiple Myeloma” NCT01179490 ↗ “Patients receive bendamustine hydrochloride intravenously (IV) over 60-180 minutes on days 1 and 2.” NCT02315157 ↗ “bendamustine hydrochloride IV over 30 minutes on days 1-2” NCT01412879 ↗ “SyB L-0501RI (Bendamustine Hydrochloride for Injection)” NCT03900377 ↗ “Drug: Bendamustine Hydrochloride Injection” NCT01657955 ↗ “bendamustine hydrochloride [bendamustine]” NCT03269669 ↗ “bendamustine hydrochloride (bendamustine)” NCT01886872 ↗ “Drug: bendamustine hydrochloride” NCT00984542 ↗ “Drug: bendamustine hydrochloride” NCT07593482 ↗ “Drug: Bendamustine Hydrochloride” NCT04115631 ↗ “Drug: Bendamustine hydrochloride” NCT01108341 ↗ “bendamustine hydrochloride” NCT00867503 ↗ |
| Known as | Bendamustine hydrochloride injection | “Bendamustine hydrochloride injection 120 mg/m² or 100 mg/m² intravenously (IV) on Day 1 and Day 2 of 21-day cycle” NCT04569838 ↗ |
| Known as | Bendamustine hydrochloride; Ribomustin | “Bendamustine hydrochloride; Ribomustin” NCT03492775 ↗ |
| Known as | Bendamustine( Leweixin, Chia Tai TIANQING, China) | “Bendamustine( Leweixin®, Chia Tai TIANQING, China)” NCT04762745 ↗ |
| Known as | Levact | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02467946 ↗ |
| Known as | Levact (Bendamustine) | “Levact (Bendamustine)” NCT02237261 ↗ |
| Known as | Ribomustin | “Bendamustine 90mg/mq for a maximum of 4 cycles Other Name: Ribomustin” NCT05660993 ↗ |
| Known as | Robimustin : Bendamustine | “Robimustin : Bendamustine” NCT01045681 ↗ |
| Known as | SDX-105 | “SUMMARY: This is a multi-center open label study to evaluate the safety and effectiveness of Treanda™ (also known as bendamustine HCl or SDX-105) in patients who have indolent...” NCT00139841 ↗ |
| Known as | SyB L-0501 | “The purpose of this study is to assess the antitumor effects and safety of bendamustine hydrochloride (SyB L-0501) in patients with indolent B-cell non-Hodgkin's lymphoma or...” NCT00612183 ↗7“The purpose of this study is to assess the tolerability, pharmacokinetics and antitumor effect of bendamustine hydrochloride (SyB L-0501) in patients with indolent B-cell...” NCT00389051 ↗ “A Multicenter, Open-Label, Phase 2 Study of SyB L-0501 (Bendamustine Hydrochloride) for Patients With Multiple Myeloma” NCT01179490 ↗ “bendamustine (SyB L-0501: 90 mg/m\^2/day)” NCT01849848 ↗ |
| Known as | SyB L-0501RI | “SyB L-0501RI (Bendamustine Hydrochloride for Injection)” NCT03900377 ↗ |
| Known as | Treanda | “SUMMARY: This is a multi-center open label study to evaluate the safety and effectiveness of Treanda™ (also known as bendamustine HCl or SDX-105) in patients who have indolent...” NCT00139841 ↗ |
| Known as | Trenda | “Ofatumumab (Azerra) + bendamustine (Trenda)” NCT01131247 ↗ |
| Action | Inhibit | “Drugs used in chemotherapy, such as bendamustine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.” NCT00939328 ↗ |
| Modality | Small molecule | “Bendamustine is a bifunctional alkylating agent with proven activity in myeloma.” PMID 25911554 ↗ Apr 2015 |
| Route | Intravenous | “30-60 minute intravenous infusion” NCT00069758 ↗ |